Enteral stents are a palliative treatment option for constrictions caused primarily by various cancers. The primary cancers which cause constrictions requiring the use of enteral stents are esophageal cancer, gastric cancer, pancreatic cancer, and colorectal cancer. There are three primary enteral stents; the covered enteral stent, the partially covered enteral stents, and the non-covered enteral stent.
The Middle Eastern and African market for enteral stents, which encompasses five countries and includes esophageal stents, gastrointestinal stents, and colonic stents, was valued at approximately $2.7M in 2016. The market is expected to grow at a CAGR of 3.3%, to reach a valuation of $3.4M in 2023.
The key drivers of this market during the forecast period are:
- Increased cancer rates driven by an increased intake of toxins such as tobacco and alcohol.
- Increase in diseases such as diabetes, as well as obesity.
- Development of stenting technology.
Enteral stents market is a leading non-vascular stents market. This market includes esophageal stents, gastroduodenal stents, and colonic stents, and is divided into three segments: fully covered enteral stents, partially covered enteral stents, and non-covered enteral stents. As a whole, the enteral stents market is increasing, primarily due to globally rising cancer rates, specifically esophageal, stomach, pancreatic, and colorectal cancers, and by an increased awareness of stenting as a palliative treatment.
Globally, fully covered stents command the largest market share. They tend to be preferred over partially covered and non-covered enteral stents, especially in the case of esophageal stents, as they have the lowest risk of tumor or tissue ingrowth. The non-covered enteral stents market, however, is a declining market, as they are more likely to result in tumor ingrowth and result in further complications. This trend is seen throughout the global enteral stents market.
There are three key players in the international enteral stents market. Boston Scientific is the leading company in the enteral stents market thanks to an extensive product line and a presence in all segments of the enteral stents market. Its presence was further strengthened by the acquisition of EndoChoice, a former smaller player in the enteral stents market. The other two key players in the enteral stents market are Cook Medical and Taewoong Medical. Cook Medical has established a strong presence despite a small product line, while Taewoong Medical has a more extensive product portfolio.
The report "MediPoint: Enteral Stents - Middle East and Africa Forecast and Market Analysis" examines the enteral stents market in five major Middle East and Africa markets: Egypt, Israel, Saudi Arabia, South Africa, and the UAE. This report provides insight into the adoption trends, market dynamics, competitive landscape, marketed products, current players, as well as market outlooks in the Middle East and Africa market.
Table 8: Product Portfolio -Taewoong Medical
Table 9: Other Players Assessment
List of Figures
Figure 1: Enteral Stents Sales for Europe, by Country, 2016 and 2023